TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today the pricing of an
underwritten offering of 13,750,000 shares of its common stock, offered
at a price of $2.40 per share. The gross proceeds to TherapeuticsMD from
this offering are expected to be approximately $33 million, before
deducting underwriting discounts, commissions, and other estimated
offering expenses payable by TherapeuticsMD. All of the shares in the
offering are to be sold by TherapeuticsMD. The offering is expected to
close on or about September 30, 2013, subject to the satisfaction of
customary closing conditions.
Stifel, Cowen and Company, and Lazard Capital Markets acted as joint
book-running managers for the offering. Noble Financial Capital Markets
served as financial advisor for the transaction.
A shelf registration statement on Form S-3 relating to the offering of
the shares of common stock described above was filed with the Securities
and Exchange Commission ("SEC") and declared effective by the SEC. A
prospectus supplement relating to the offering will be filed with the
SEC and will be available on the SEC's web site at www.sec.gov.
When available, copies of the prospectus supplement may also be obtained
from Stifel, Nicolaus & Company, Incorporated, Attn: Syndicate, One
Montgomery Street, 36th Floor, San Francisco, CA 94104, by telephone at
(415) 364-2720 or by e-mail at syndprospectus@stifel.com;
from Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department or
by telephone at (631) 274-2806; and from Lazard Capital Markets LLC, 30
Rockefeller Plaza, New York, NY 10020 or via telephone at (800) 542-0970.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a women’s healthcare company focused on
developing and commercializing products targeted exclusively for women.
We manufacture and distribute branded and generic prescription prenatal
vitamins, as well as over-the-counter vitamins and cosmetics, under our
vitaMedMD® and BocaGreenMD™ brands. We are currently
developing advanced hormone therapy pharmaceutical products designed to
alleviate the symptoms of and reduce the health risks resulting from
menopause-related hormone deficiencies. We are also evaluating various
other potential indications for our hormone technology, including oral
contraception, preterm birth, vulvar and vaginal atrophy, and premature
ovarian failure.
vitaMedMD® and TherapeuticsMD® are registered
trademarks of TherapeuticsMD, Inc. BocaGreenMD™ is a trademark of
TherapeuticsMD, Inc.
Except for the historical information contained herein, the matters
set forth in this press release, including statements regarding
TherapeuticsMD’s expectations with respect to the gross proceeds from
and the closing of the offering, are forward-looking statements within
the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially, including the risks and uncertainties associated with
market conditions, the satisfaction of customary closing conditions
related to the offering, risks and uncertainties associated with
TherapeuticsMD’s business and finances in general, and other risks
detailed in TherapeuticsMD’s annual report on Form 10-K filed on March
12, 2013 and other filings with the SEC. These forward-looking
statements are based on current information that may change and you are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and TherapeuticsMD undertakes no obligation to
revise or update any forward-looking statement to reflect events or
circumstances after the issuance of this press release.
Copyright Business Wire 2013